Infliximab biosimilar - Axxo

Drug Profile

Infliximab biosimilar - Axxo

Latest Information Update: 26 Sep 2013

Price : $50

At a glance

  • Originator AXXO
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase Unknown Autoimmune disorders; Crohn's disease

Most Recent Events

  • 26 Sep 2013 Investigation in Crohn's disease in Germany (IV)
  • 26 Sep 2013 Investigation in Autoimmune disorders in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top